Hossein Borghaei DO

Oncology•Philadelphia, PA

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Medical Oncology

Join to View Full Profile

333 Cottman Ave# FoxPhiladelphia, PA 19111
Phone+1 215-728-6900
Fax+1 215-728-3639

Summary

Dr. Hossein Borghaei is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Temple University Hospital and Fox Chase Cancer Center-American Oncologic Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 21 years. He specializes in hematologic oncology and thoracic cancer and is experienced in immunotherapy, non-small cell lung cancer, urologic oncology, biomedical research, and combined modality therapy.

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Graduate HospitalResidency, Internal Medicine, 1997 - 2000
Philadelphia College of Osteopathic MedicineClass of 1996

Certifications & Licensure

PA State License 1997 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2007 Jul 05
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2011 Oct 20
Terminated
Phase 1, Phase 2
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
Completed
Phase 2
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer Start of enrollment: 2012 Aug 23
Completed
Not Applicable
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Start of enrollment: 2015 Mar 01
Terminated
Not Applicable
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
ACTIVE_NOT_RECRUITING
PHASE3
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Start of enrollment: 2017 Mar 29
Terminated
Phase 1, Phase 2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Start of enrollment: 2020 Oct 08
RECRUITING
PHASE2
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC Start of enrollment: 2022 Jul 13
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.
Philip C Mack, Mary W Redman, Hanna Tukachinsky, David E Kozono, Katherine Minichiello
Clinical Cancer Research. 2025-08-14
2 citations
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicent...
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, Solange Peters, Roy S Herbst
Lancet. 2025-06-14
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate ...
Solange Peters, Meredith M Regan, Luis G Paz-Ares, Martin Reck, Hossein Borghaei
Journal of Thoracic Oncology. 2025-06-03

Press Mentions

Histologic Subtype May Inform Immunotherapy Strategy in mNSCLC Without Targetable MutationsJuly 2nd, 2025
Overturning Survival Expectations for Often-Deadly Lung CancerFebruary 27th, 2025
Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
Join now to see all